Owlet (OWLT) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
11 May, 2026Executive summary
Q1 2026 revenue reached $22.5 million, up 6.4% year-over-year, driven by strong subscription growth and offset by a decline in hardware sales.
Subscription revenue hit a record $2.7 million, with over 115,000 paying subscribers and monthly recurring revenue surpassing $1 million.
Gross margin improved to 54.5%, up 80 basis points year-over-year despite tariff impacts.
Net loss was $3.3 million, reversing from net income in Q1 2025, due to higher operating expenses and legal costs.
Leadership transition occurred in April 2026, with Kurt Workman resuming the CEO role to drive strategic focus and growth.
Financial highlights
Q1 2026 revenue was $22.5 million, with subscription revenue at $2.7 million and hardware revenue at $19.8 million.
Subscription gross margin was 67.4%; overall gross margin was 54.5%.
Operating expenses rose to $17.7 million, or 79% of revenue, mainly due to compensation and headcount.
Q1 operating loss was $5.5 million; net loss was $3.3 million; adjusted EBITDA was $(1.5) million.
Cash and cash equivalents stood at $35.5 million at quarter-end; net cash used in operating activities was $5.0 million.
Outlook and guidance
2026 revenue guidance revised to $118–$122 million (12–15% growth), down from $126–$130 million.
Adjusted EBITDA guidance raised to $7–$9 million (250–350% growth), up from $3–$5 million.
Gross margin expected at 50–52% for 2026; tariff baseline set at 15% for the year.
Management believes current liquidity is sufficient for at least the next 12 months.
Revenue outlook reflects exit from lower-margin channels and conservative sell-through assumptions.
Latest events from Owlet
- Record revenue and FDA-cleared status drive growth in pediatric health monitoring.OWLT
Investor presentation1 Apr 2026 - Up to 9.6 million shares registered for resale by major holders; no proceeds to the company.OWLT
Registration Filing10 Mar 2026 - Record revenue, margin, and subscriber growth; strong 2026 outlook with global and AI expansion.OWLT
Q4 20255 Mar 2026 - Q1 revenue up 43% with record margin, breakeven EBITDA, and raised guidance amid ongoing risks.OWLT
Q1 20253 Feb 2026 - Dual FDA clearances and strong retail momentum position the company for rapid growth and margin expansion.OWLT
TD Cowen’s 8th Annual Future of the Consumer Conference1 Feb 2026 - Q2 revenue up 58% to $20.7M, gross margin 50%, but going concern risk remains.OWLT
Q2 20241 Feb 2026 - Q3 revenue up 141% to $22.1M, record margin, positive EBITDA, but liquidity risks remain.OWLT
Q3 202414 Jan 2026 - Record 2024 results, new FDA-cleared products, and margin gains set up for 2025 profitability.OWLT
Q4 202426 Dec 2025 - Proposes up to $100M in securities offerings to fund digital infant health solutions amid key risks.OWLT
Registration Filing16 Dec 2025